Pfizer

Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

Retrieved on: 
Thursday, June 8, 2023
Isavuconazonium, LR, Patient, Pharmaceutical industry, Allschwil, EU, Pfizer

53 LR

Key Points: 
  • 53 LR
    Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totaling USD 26.25 million to Basilea.
  • Under the terms of the agreement, Basilea remains eligible for milestone payments of up to approximately CHF 515 million, in addition to receiving mid-teen royalties on net sales.
  • Cresemba has been approved in 73 countries to date and is currently marketed in 67 countries, including the United States, most EU member states and additional countries inside and outside of Europe.
  • In 2022, total global in-market sales of Cresemba amounted to USD 373 million, a 15 percent growth year-on-year.1

Dr.Evidence® Appoints Ken Kobayashi, MD, FACP to its Medical Strategy Advisory Board

Retrieved on: 
Tuesday, June 6, 2023
Software, Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Science, Health, MSAB, Kobayashi, Drug development, Swansea University Medical School, Chair, MB, FACP, AB, Janssen, Multimedia, Doctor of Philosophy, AstraZeneca, Bachelor of Science, National Cancer Institute, Criticism of the Food and Drug Administration, SCM, Bachelor of Medicine, Bachelor of Surgery, Novartis, Daiichi Sankyo, MPH, Feinberg School of Medicine, BA, Food, Pfizer, Medical device, Pharmaceutical industry, Washington University in St. Louis, MD

Dr.Evidence is pleased to announce the appointment of Ken Kobayashi, MD, FACP to the MSAB.

Key Points: 
  • Dr.Evidence is pleased to announce the appointment of Ken Kobayashi, MD, FACP to the MSAB.
  • He joins Chair, Calum MacRae, MB, ChB, PhD, BSc, and members, Michael Klag, MD, MPH, Frank Rockhold, PhD, ScM, BA, and David Tovey, MD.
  • View the full release here: https://www.businesswire.com/news/home/20230606005160/en/
    Dr.Evidence® Appoints Ken Kobayashi, MD, FACP to its Medical Strategy Advisory Board.
  • Kobayashi received his MD from Northwestern University Medical School, Chicago, IL, and his AB from Washington University, St. Louis, MO.

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on: 
Tuesday, June 6, 2023
Science, Thought Leadership, Biotechnology, Research, Pharmaceutical, Health, Professional Services, Clinical Trials, Goldman Sachs controversies, Webcast, PFE, Inc., Goldman, Pfizer, Conference, NYSE

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:00 a.m. Pacific Daylight Time.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:00 a.m. Pacific Daylight Time.
  • To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

Treating COVID with Metformin Reduces Long COVID Rates

Retrieved on: 
Friday, June 9, 2023
University, Parsemus Foundation, COVID-19, Ivermectin, Research, Multimedia, COVID, The Lancet, Preprint, MD, Metformin, Patient, University of Minnesota Medical School, Randomized controlled trial, Viral load, Health, Death, Pfizer, Disease, Pharmaceutical industry, Long COVID

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.

Key Points: 
  • MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
  • The randomized, quadruple-blinded, placebo-controlled clinical trial was the first in the country to study whether these medications could prevent severe outcomes and Long COVID.
  • The trial found that people who took metformin within seven days after the onset of COVID symptoms were 41% less likely to experience Long COVID than those who had placebo—with a 63% reduction if metformin was started within four days.
  • As the first COVID treatment proven to reduce Long COVID in a randomized controlled trial, metformin is safe, accessible and low-cost.

Treating COVID with Metformin Reduces Long COVID Rates

Retrieved on: 
Friday, June 9, 2023
University, Parsemus Foundation, COVID-19, Ivermectin, Research, COVID, The Lancet, Preprint, MD, Metformin, Patient, University of Minnesota Medical School, Randomized controlled trial, Viral load, Health, Death, Pfizer, Disease, Pharmaceutical industry, Long COVID

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.

Key Points: 
  • MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
  • The randomized, quadruple-blinded, placebo-controlled clinical trial was the first in the country to study whether these medications could prevent severe outcomes and Long COVID.
  • The trial found that people who took metformin within seven days after the onset of COVID symptoms were 41% less likely to experience Long COVID than those who had placebo—with a 63% reduction if metformin was started within four days.
  • As the first COVID treatment proven to reduce Long COVID in a randomized controlled trial, metformin is safe, accessible and low-cost.

Promosome LLC Sues Moderna, Pfizer, and BioNTech for COVID-19 Vaccine Patent Infringement

Retrieved on: 
Wednesday, June 7, 2023
Vaccine, 1836 U.S. Patent Office fire, BioNTech, Patent, CAB, JES, COVID-19, Messenger, Moderna, SAN, Scripps Research, Pharmaceutical industry, Pfizer

SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.

Key Points: 
  • SAN DIEGO, June 7, 2023 /PRNewswire/ -- Promosome LLC, represented by Susman Godfrey, has filed major patent infringement actions against pharmaceutical behemoths Moderna, Pfizer, and BioNTech.
  • The suits allege that the mRNA-based COVID-19 vaccines produced by these companies violate patented technology owned by Promosome.
  • While Moderna did not license the '179 Patent, mRNA sequence reverse engineering shows that Moderna took the patented technology for its vaccine, Spikevax®.
  • The second lawsuit, against Pfizer and BioNTech, alleges that Pfizer and BioNTech's joint COVID-19 vaccine Comirnaty® willfully infringes the '179 Patent.

Purpose Built Communities Names Curtis Hunter Vice President of Marketing and Communications

Retrieved on: 
Tuesday, June 6, 2023
Communication, League of Women Voters of California, Laboratory, BS, Network, Purpose Built Communities, Marketing, Abbott Laboratories, The Walt Disney Company, League, MBA, American Marketing Association, Political science, Social justice, Trust, Fortune 500, Work, Florida A&M University, Greater Orlando, Association of National Advertisers, Pfizer

ATLANTA, June 6, 2023 /PRNewswire-PRWeb/ -- Purpose Built Communities announces Curtis Hunter as its new Vice President of Marketing and Communications. He brings over two decades of relevant experience to the national nonprofit from Fortune 500 companies, including The Walt Disney Company, Pfizer, and Abbott Laboratories. In this role, he will lead all marketing and communications efforts for Purpose Built and its Network.

Key Points: 
  • ATLANTA, June 6, 2023 /PRNewswire-PRWeb/ -- Purpose Built Communities announces Curtis Hunter as its new Vice President of Marketing and Communications.
  • In this role, he will lead all marketing and communications efforts for Purpose Built and its Network.
  • Hunter will oversee brand, marketing strategy, creative, stakeholder insights, and communications for Purpose Built.
  • Additionally, he will consult with Purpose Built Network Members to help facilitate the development of local marketing and communications strategies.

COVID-19 vaccination: No serious side effects in young children

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, HealthPartners, Seizure, Denver Health Medical Center, Partnership, Vaccination, Coronavirus, Stroke, COVID-19, Myocarditis, Kaiser Permanente, Doctor of Philosophy, Parent, Messenger, CDC, Vaccine Safety Datalink, Marshfield Clinic, MD, Division, Risk, Korea Disease Control and Prevention Agency, Kaiser Permanente Arena, MPH, Immunization, Roger Hawkins (drummer), Family, Encephalitis, Pfizer, Pericarditis, Pharmaceutical industry, Pediatrics, Moderna, Research

OAKLAND, Calif., June 6, 2023 /PRNewswire/ -- A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children (most of them age 4 and younger) found no indications of serious side effects. The study, published June 6 in Pediatrics, was led by the Kaiser Permanente Division of Research in partnership with the Centers for Disease Control and Prevention.

Key Points: 
  • OAKLAND, Calif., June 6, 2023 /PRNewswire/ -- A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children (most of them age 4 and younger) found no indications of serious side effects.
  • The Pediatrics study marks the first analysis looking for serious side effects from the mRNA vaccines in young children.
  • The study examined medical records for 23 serious potential side effects, including outcomes such as blood clots, seizures, stroke, and brain inflammation.
  • "Parents can protect their young children from COVID-19 in the same way they vaccinate their children to protect from other serious childhood diseases."

Ryan Stewart Joins MTS Health Partners

Retrieved on: 
Tuesday, June 6, 2023
WCAS, Partner, Research, Biopharma LLC, Sale, MTS, Warburg Pincus, Solomon Partners, Temasek, Leonard Green & Partners, Prime, CTI, Therapy, SVB Securities, Pharmaceutical industry, Pfizer

NEW YORK, June 6, 2023 /PRNewswire/ -- MTS Health Partners ("MTS"), a leading healthcare-dedicated investment bank that provides strategic and financial advice to the global healthcare industry, announced today that Ryan Stewart has joined the firm as a Partner in its New York office. As a key member of the MTS team, Ryan will work with Michael Ludwig to drive the firm's strategic initiatives in the rapidly evolving healthcare technology sector and expand the firm's industry-leading Healthcare Technology team.

Key Points: 
  • NEW YORK, June 6, 2023 /PRNewswire/ -- MTS Health Partners ("MTS"), a leading healthcare-dedicated investment bank that provides strategic and financial advice to the global healthcare industry, announced today that Ryan Stewart has joined the firm as a Partner in its New York office.
  • As a key member of the MTS team, Ryan will work with Michael Ludwig to drive the firm's strategic initiatives in the rapidly evolving healthcare technology sector and expand the firm's industry-leading Healthcare Technology team.
  • "We are thrilled to welcome Ryan to the MTS team," said Curtis Lane, Founding Partner of MTS.
  • "I am deeply honored to join MTS," said Ryan.

Over $5 million to accelerate cancer research and innovation in Quebec - Oncopole strengthens its leadership role in the oncology ecosystem with the support of numerous partners

Retrieved on: 
Monday, June 5, 2023
Canada, Heart, GSK, Partnership, Government Affairs Institute, Cancer, Innovation, Research, Science, Investment, Patient, Access, Foreign policy, Policy, Pfizer, Pharmaceutical industry

These new partnerships will support the development of programs to mobilize financial and human resources for research into targeted and promising oncology treatments.

Key Points: 
  • These new partnerships will support the development of programs to mobilize financial and human resources for research into targeted and promising oncology treatments.
  • "We are very excited to be able to count on new partners," said Carole Jabet, Director of Oncopole and Scientific Director of the FRQS.
  • "Merck Canada is pleased to announce its renewed commitment to Oncopole in support of oncology research.
  • "GSK is proud to support Oncopole and its synergistic role in oncology innovation.